



LKT Laboratories, Inc.

SGX-523

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID S2792

CAS No. 1022150-57-7

Chemical Name

Synonym SGX523

Formula $C_{18}H_{13}N_7S$

Formula Wt. 359.41

Melting Point


Purity $\geq 98\%$

Solubility DMSO 3 mg/mL warmed
(8.34 mM)
Water Insoluble
Ethanol Insoluble

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description SGX-523 is an inhibitor of MET that exhibits anticancer chemotherapeutic activity. SGX-523 inhibits growth of cells and tumors in models of non-small cell lung cancer (NSCLC). SGX-523 also improves the efficacy of co-administered treatments, further suppressing growth in animal models of lung cancer, breast cancer, and pancreatic cancer.



Bulk quantities available upon request

Product ID	Size
S2792	1 mg
S2792	5 mg
S2792	25 mg

References Zhang YW, Staal B, Essenburg C, et al. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR. *Mol Cancer Ther.* 2013 Aug;12(8):1429-41. PMID: 23720767.

Zhang YW, Staal B, Essenburg C, et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. *Cancer Res.* 2010 Sep 1;70(17):6880-90. Erratum in: *Cancer Res.* 2011 Apr 1;71(7):2804. PMID: 20643778.

Buchanan SG, Hendle J, Lee PS, et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. *Mol Cancer Ther.* 2009 Dec;8(12):3181-90. PMID: 19934279.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.